UK drug development company ValiRx (AIM:VAL) has been in the headlines probably more than it would have liked since the beginning of November, when a trading update triggered a series of selloffs and a sharp decline in price.
The reaction, or possibly overreaction, has mostly removed the froth whipped up earlier this autumn after two private investors increased their holdings – one dutifully following it up on Twitter.
The rest of this article is not available as it is for members only. Please log in below or visit the registration page for Armchair Trader+ to see the benefits of becoming a member.
Log In or Sign Up to Continue Reading
Already an Armchair Trader+ member? Log in here:
Not a member yet? Sign up for your free trial or check out the benefits of membership.
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader+ for further details on the benefits of becoming a member.